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Abstract 0 Expression plasmid DNA for the human interleukin-1 receptor
antagonist (IL-1ra) protein was formulated with nonionic:cationic (NC)
liposomes or phosphatidylcholine:cationic (PC) liposomes and applied to
the auricular skin of hamsters in single- and multiple-dose protocols.
Confocal microscopy identified delivery of plasmid DNA proximal to
perifollicular cells, and successful transfection of perifollicular cells was
identified by immunohistochemistry and ELISA. Skin treated for 3 days
with the NC liposomes had statistically significant levels of transgenic
IL-1ra present for 5 days post-treatment. Expression of transgenic
IL-1ra was specific to areas of skin treated with NC liposomes but not
PC liposomes. The results indicate that the NC liposomes can deliver
expression plasmid DNA to perifollicular cells and mediate transient
transfection in vivo.
Introduction
Topical delivery of gene vectors to cells within the skin is
an attractive strategy for gene therapy of many human
diseases, including a number of dermatological conditions
thought to be mediated by abnormal regulation of soluble
cytokines.1-5 Although it is highly unlikely that macromol-
ecules can permeate the stratum corneum, the presence of
follicles and associated structures may not only allow localized
delivery to viable skin cells, but may also promote diffusion
of transgenic soluble proteins into the surrounding tissue and/
or the systemic circulation. The development of pharmaceuti-
cal reagents that can mediate transfection of epidermal cells
would have far reaching experimental and therapeutic ap-
plications. For topical gene therapy to be successful, it will
be necessary to optimize delivery of recombinant DNA to
accessible target cells within living skin strata with vehicles
that can overcome the formidable permeability barriers of the
skin and its appendages.
Initial attempts at gene delivery to living skin have been
hampered by problems associated with the delivery of charged
macromolecules beyond the stratum corneum and have fo-
cused mainly on parenteral methods. These methods have
included direct injection of plasmid DNA into the upper
epidermis as well as pneumatic acceleration of metallic
microparticles coated with plasmid DNA into the skin.6,7
Although some degree of skin cell transfection has been
achieved by these methods, neither appears likely to allow
for the delivery of plasmid DNA to a large number of target
cells on a cost-effective, therapeutic basis. Although recent
studies have reported promising initial results with cationic
liposomes for topical transfection, questions remain regarding
the feasibility of these methods for the delivery of potentially
therapeutic transgenes.8,9 Further, the effects of composition
and preparation methods of the liposomal formulations on the
integrity and stability of expression plasmid DNA have not
been addressed. Current knowledge regarding the types of
cells that may be transfected and the kinetics of transgene
expression following topical application of liposomal gene
vectors is also limited. Finally, given the ubiquitous existence
of lysosomal galactosidase as an inducible enzyme within
many types of skin cells, the reliability of E. coli â-galactosi-
dase as a definitive reporter gene for in vivo transfection
studies into skin needs to be re-examined.
We previously reported that topical application of a novel
nonionic liposomal formulation developed in our laboratories
enhanced the delivery of macromolecules such as interferons,
cyclosporin-A, and growth factors into the pilosebaceous units
of the hamster ear and into dermal tissues of hairless mice.10
More efficient delivery of these macromolecules was achieved
compared with those obtainable with conventional phospho-
lipid-based liposomes and conventional solutions and gels.11-14
Further, it was found that clinically significant levels of
macromolecular proteins could be delivered to the vicinity of
target sites by our nonionic formulations.15,16
Based on these studies we hypothesized that expression
plasmid DNA could be substituted as the charged macromol-
ecule in nonionic liposomal formulations. The goal of this
substitution was the development of a topical formulation with
two essential physicochemical properties required for trans-
fection of perifollicular skin cells in vivo; they are (1) trans-
dermal delivery of large amounts of plasmid DNA proximal
to perifollicular cells, and (2) intracellular delivery of the DNA
into the target cells. Because successful gene delivery in vivo
is best assessed with theoretically relevant and biologically
active transgenes (as opposed to marker transgenes), the
cDNA for human interleukin-1 receptor antagonist protein
was used as a transgene in our studies.17-19 In this report,
we show that an expression plasmid encoding the cDNA for
human IL-1ra protein formulated with nonionic and cationic
lipid components can be used as a topical pharmaceutical
reagent for the transient transfection of skin cells in vivo.
Materials and Methods
Preparation and Purification of Plasmid DNAsExpression
plasmids used in these studies were derived from the eukaryotic
expression vector pSG5 (Stratagene), and utilize the SV40 LTR as a
promoter and the SV40 polyadenylation sequence. The cDNA for
human interleukin-1 receptor antagonist protein (gift of Immunex
Inc.) was cloned into the BamHI site of pSG5 to yield pSG5IL-1ra.
The gene for Escherichia coli (E. coli) â-galactosidase was cloned into
the BamHI site of pSG5 to yield pSG5lacZ. The orientation of the
transgene within recombinant plasmids was confirmed by a combina-
tion of restriction endonuclease mapping and dideoxynucleotide
sequencing. Plasmid DNA was prepared from the DH5-a strain ofX Abstract published in Advance ACS Abstracts, May 1, 1997.
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E. coli transformed with the recombinant plasmids and grown in LB
broth containing ampicillin (50 µg/mL). Plasmid DNA was purified
by a modification of the alkaline lysis method followed by two separate
bandings in cesium chloride equilibrium gradients.20 Ethidium
bromide was extracted from the DNA with butanol, and the batches
were then dialyzed extensively against purified water (Millipore) and
precipitated with ethanol. Aliquots of the plasmids were then
resuspended in purified water, filter sterilized through 0.22-µm filters
(Millipore) and stored at -20 °C until use. The purity and concentra-
tion of all the plasmid preparations were confirmed by electrophoresis
in 1% agarose gels containing ethidium bromide, and UV spectroscopy
at 260 and 280 nm (Beckman Spectrometer). DNA was also screened
for the presence of bacterial endotoxin (Sigma), and batches with an
endotoxin concentration exceeding 15 endotoxin units per milliliter
were discarded. In the case of pSG5IL-1ra, all batches of purified
DNA were tested for the presence of recombinant human IL-1ra
protein by ELISA. None of the DNA used for the in vivo studies
contained detectable levels of human IL-1ra (detection limits <29 pg/
mL). Fluorescently labeled pSG5IL-1ra plasmid was produced in an
identical fashion except that ethidium bromide intercalated into the
DNA during the purification process was retained and excess non-
incorporated ethidium bromide was removed by extensive dialysis in
Tris-EDTA buffer.
Preparation of Nonionic/Cationic-Based Liposomal Form-
ulationssThe nonionic/cationic (NC) liposomal formulations used in
the experiments contained glyceryl dilaurate (GDL; IGI, Inc.; >90%
1,3-isomer), cholesterol (CH; IGI, Inc.), polyoxyethylene-10-stearyl
ether (POE-10; IGI, Inc.), and 1,2-dioleoyloxy-3-(trimethylammonio)-
propane (DOTAP; Avanti Polar Lipids) at a weight percent ratio of
50:15:23:12. The lipid mixture also contained R-tocopherol (1% by
weight of total lipids; Eastman Kodak). Appropriate amounts of the
lipids were mixed and melted at 70 °C in a sterile polystyrene
centrifuge tube. The lipid melt was then filtered through a 0.22-µm
filter (Nuclepore), and the filtrate was reheated in a water bath at
70 °C prior to being drawn into a sterile syringe. A second syringe
containing sterile, autoclaved, double-distilled water was preheated
to 65 °C and connected via a three-way sterile stopcock to the lipid
phase syringe. The aqueous phase was then slowly injected into the
lipid phase syringe. The mixture was rapidly passed back and forth
between the two syringes while being cooled under cold tap water
until the mixture was at room temperature and then it was stored at
4 °C until use. The total lipid concentration in the suspension was
100 mg/mL.
The resulting NC liposomal suspensions were examined with a
Nikon Diaphot light microscope to assure integrity and quality of the
liposomal preparations. Immediately before use in the in vivo
experiments, the liposomal suspension was sonicated for 20 min at
room temperature, and an equal volume of aqueous pSG5IL-1ra or
pSG5lacZ-DNA solution (7 mg DNA/mL) was added by inversion
mixing followed by incubation at room temperature for 45 min.
Control formulations contained no DNA.
Preparation of Phospholipid-Based Liposomal Form-
ulationssLarge unilamellar liposomes (LUV) were prepared contain-
ing egg phosphatidylcholine (PC; Avanti Polar Lipids):CH:DOTAP and
R-tocopherol (1% by weight of total lipids; Eastman Kodak) in a 1:0.5:
0.1 molar ratio. A reverse-phase evaporation method based on that
reported by Szoka and Papahadjopoulos 21 was used in the prepara-
tion of the LUVs. The lipids were dissolved in a chloroform:methanol
mixture [2:1 (v/v)]. Isotonic 0.05 M HEPES buffer (Sigma Chemical
Company), pH 7.4, was added to form a clear mixture. The solvent-
to-buffer ratio was 6:1 (v/v). The solvents were removed with a
rotoevaporator (Buchii) maintained at 45 °C. The total lipid concen-
tration in the suspension was 75 mg/mL. The resulting liposomal
suspensions were examined with a Nikon Diaphot light microscope
to assure integrity and quality of the liposomal preparations. The
liposomes were then sonicated for 20 min at room temperature before
the addition of an equal volume of aqueous pSG5IL-1ra DNA solution
(7 mg/mL). The liposomal DNAmixture (liposome-DNA formulation)
was then allowed to incubate at room temperature for 45 min prior
to topical application to the ventral side of hamster ears.
In Vivo ExperimentssAnimal experiments were conducted under
institutional guidelines with approval by the University Committee
on the Use and Care of Animals (UCUCA). Male golden Syrian
hamsters, 10 weeks old, were purchased from Charles River Breeding
Laboratories (Wilmington, MA) and were maintained for 2 weeks at
a photoperiod of 14 h of light and 10 h of darkness to maximize
androgen-dependent sebaceous gland activity and thus control their
size.22 The ventral sides of the hamster ears were carefully shaved
1 day prior to the experiments. The hamsters were anesthetized with
a single dose of sodium pentobarbital (0.25 cc of 40 mg/kg intraperi-
toneal injection). Following anesthetization, 50 µL of the test
formulation containing the pSG5IL-1ra plasmid DNA were applied
to the ventral surface of one ear, twice daily for 3 days. The
contralateral ear was treated with an equivalent amount of liposomes
without plasmid DNA (control). Additionally, a set of control animals
(n ) 4) were treated as just described with NC liposomes containing
pSG5lacZ plasmid DNA. The total amount of lipid applied per ear of
NC-based liposomes was 15 mg (2.5 mg/dose), and the total lipid
applied per ear with the PC-based liposomes was 11.25 mg (1.875
mg/dose). For both NC- and PC-based liposome-DNA formulations,
the total amount of DNA applied was 1.05 mg (0.175 mg/dose). One
day later (15 h after the last application of the test formulations),
the hamsters were sacrificed and the ears were excised by dissection
across the base. The kinetics of transgene expression following topical
application of NC liposomal pSG5IL-1ra-plasmid DNA and blank NC
liposomes were studied by sacrificing treated animals at 1, 3, 5, and
8 days after the last application. For each given time point, at least
three animals were used per formulation tested. Ears of untreated
animals were also used as negative controls. All experiments were
carried out under non-occluded conditions. At the time of sacrifice,
the ears were isolated by sharp dissection, weighed, and measured
along each border (to calculate the surface area exposed to treatment),
then processed as described next. One milliliter of blood was also
collected from each animal immediately following sacrifice and
centrifuged at 14 000 rpm (Beckman) for 10 min at 4 °C. The serum
was collected and assayed for IL-1ra content.
Confocal Laser Scanning MicroscopysEar tissue was embed-
ded in OCT (optimum cutting temperature compound) (Miles Labo-
ratories, Elkhart Lake, IN) and frozen in isopentane-containing dry
ice. The tissue blocks were stored at -80 °C before sectioning. Blocks
were sectioned at 20 µm with a Tissue-Tec II model 4553 cryostat
(Miles Laboratories, Inc., Naperville, IL) and placed on poly-L-lysine
double-coated slides. Immediately before viewing, the slides were
mounted with Vecta-Shield mounting media (Vector Laboratories,
Burlingame, CA). The sections were examined with a Bio-Rad MRC
600 laser scanning confocal microscope (Bio-Rad Microscience Div.,
Cambridge, MA), and analyzed with the CoMOS program. The
imaging procedure employed has already been described in detail.23
The light source was argon-krypton laser equipped with a 520-nm
filter wheel and cubes for detection of emitted light. Images were
resized with Adobe Photoshop Version 3.0 (Adobe Systems, Inc.,
Mountain View, CA). Prints of the digital images were made with a
Kodak XLS 8600 PS printer (Eastman Kodak Company, Rochester,
NY).
Southern AnalysissAnimals treated with the NC liposomal
pSG5IL-1ra-plasmid DNA formulations (50 mg/mL NC liposomes,
3.5 mg/mL DNA) were sacrificed at 1, 4, 6, 8, 12, and 24 h after
application. Those treated with the aqueous DNA solutions (3.5 mg/
mL) were examined at 12 and 24 h after application. Following
sacrifice, the ears were cut at the base and pinned to a board with
the ventral side facing up. The ventral side was swabbed several
times with PBS-soaked tissue paper and stripped with tape until all
hair was removed and the surface looked shiny indicating complete
removal of the stratum corneum. The surface of the ventral ear was
swabbed several times again with PBS-soaked tissue paper before
the ventral ear was separated from the underlying cartilage. The
ventral ear was placed on a 60-mm polystyrene dish with the
epidermal side facing down. Then, 500 µL of a 0.05 M isotonic HEPES
solution (pH 7.4) was placed on the ear, and the sebaceous glands
were carefully scraped with a sterile, dull scalpel. This procedure
was carried out twice. Tissues were then minced in 1 mL of
homogenate buffer and collected in sterile Eppendorf tubes along with
the gland scrapings. Genomic DNA was isolated from the tissue
homogenates with DNAzol reagent (Life Technologies, Inc., Gaith-
ersburg, MD) according to the manufacturer's protocol. The concen-
tration of DNA isolated from each sample was determined spectro-
photometrically.
Samples (10 mg of total DNA) were loaded onto 0.8% agarose gels,
electrophoresed at 20 V for 21 h, and transferred to a Nytran
membrane. Controls included lanes containing known amounts of
pSG5IL-1ra (15 or 150 pg), both undigested and linearized by
digestion with EcoR1. The membrane was probed with [32P]-labeled
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oligonucleotide probes specific for human IL-1ra generated from a
650 bp fragment of human IL-1ra cDNA that was isolated from
pSG5IL-1ra with random hexanucleotide primers, 32P-dCTP (Amer-
sham), and Klenow fragment (BRL). Hybridization buffer included
10% dextran sulfate, 35% formamide, 5X SSC, 0.1% SDS, and 100
µg/mL of salmon sperm DNA, and hybridizations were performed
overnight at 42 °C. Membranes were washed twice for 10 min at
room temperature in 2X SSC/0.1% SDS, twice for 10 min at 65 °C in
1X SSC/0.1% SDS, and once for 10 min at 65 °C in 0.1X SSC/0.1%
SDS. Membranes were wrapped in plastic and exposed to film (Kodak
X-AR5) at -70 °C, using intensifying screens.
Detection of IL-1ra by ImmunohistochemistrysTreated ears
were embedded in OCT medium (Miles, Inc., Elkhart, IN) and frozen
in isopropyl alcohol containing dry ice. The frozen samples were
stored at -80 °C before sectioning. Serial sections (5 µm) were
obtained with a cryostat (Tissue-Tec II model 4553, Lab-Tec Products,
Miles Laboratories, Inc., Naperville, IL) and placed on poly-L-lysine
double-coated slides. The tissue sections were then immediately fixed
in 100% acetone for 10 min at 4 °C and processed with a Histostain-
SP AEC kit (Zymed Lab, Inc., South San Francisco, CA) according to
the manufacturer’s recommendations. The sections were reacted with
primary murine anti-human IL-1ra (29 ng/mL, Bachem Bioscience,
Inc., King of Prussia, PA) for 30 min. After completion of the protocol,
slides were counterstained with hematoxylin, rinsed a final time, and
mounted with 100 µL of GVA-mount before being examined and
photographed with a Nikon Optiphot microscope (Nikon, Tokyo,
Japan).
Isolation of Soluble Proteins from Various Strata of the
Hamster EarsEach ear strata (ventral skin, auricular cartilage and
dorsal skin) was isolated from the ear by sharp dissection as follows:
Following sacrifice, the ears were cut at the base and pinned to a
board with the ventral side facing up. The ventral side was swabbed
several times with PBS-soaked tissue paper and stripped with tape
until all hair was removed and the surface looked shiny, indicating
complete removal of the stratum corneum. The surface of the ventral
ear was then swabbed several times again with PBS-soaked tissue
paper before the ventral ear was separated from the underlying
cartilage. The ventral ear was then placed on a silanized glass slide
with the epidermal side facing down. Then, 500 µL of a homogenate
buffer (0.05 M isotonic HEPES at pH 7.4, 0.1% PMSF, and 0.1% HSA)
was placed on the ear, and the sebaceous glands were carefully
scraped with a sterile, dull scalpel. This procedure was carried out
twice. The ventral skin strata was then minced in 1 mL of homoge-
nate buffer and collected in sterile Eppendorf tubes along with the
gland scrapings. The cartilage and dorsal skin were minced in 1 mL
of homogenate buffer each. The samples were then sonicated on ice
for 2 min and centrifuged at 15 000 rpm for 10 min at 4 °C. The
supernatants were collected immediately and analyzed for human IL-
1ra protein.
Detection of IL-1ra ProteinsHuman IL-1ra protein was mea-
sured by a human specific IL-1ra protein immunoassay (Research and
Diagnostics Systems, Minneapolis, MN). Tissue homogenates were
assayed in triplicate, and the optical density of each sample was
determined with a spectrophotometer set at 450 nm and with the
correction wavelength set at 570 nm. A standard curve was also
prepared, using the homogenate buffer as the diluent from 0 to 2000
pg/mL. The detection limit of this ELISA was 29 pg/mL. The test
samples were compared with the standard curve to determine IL-
1ra concentration. The results are expressed as 10-9 g of human IL-
1ra/cm2 and/or 10-9 g of human IL-1ra/g tissue.
Results
The total lipid concentration of 50 mg/mL for the NC
liposomes was arrived at following toxicity screening with
cultured cells (NIH 3T3) in vitro. No toxic effects were evident
below a total lipid concentration of ∼100 mg/mL; higher
concentrations resulted in proportionally increasing cell death
indices. In comparison, commercially available cationic lipo-
somes (Lipofectin) induced cell death at much lower total lipid
concentrations.
The amount of cationic lipid used in the NC liposome-
plasmid DNA formulations was based on two factors: (a) the
maximum cationic lipid concentration that could be used
without inducing toxic effects, and (b) the amount that would
be required for near optimum complexation of DNA based on
estimates derived from a review of the literature.24-28 Optima
in lipid mixing and in vitro transfections were reported for
DNA-to-cationic lipid ratios of 0.25 to 0.5 µg/nmol.26 Several
others have also reported optimal transfection behavior at a
DNA-to-lipid charge ratio of 1.3 to 1.6.24,25,27,28 We chose a
concentration of 6 mg/mL as the maximum charged lipid
concentration. In preliminary transfection studies with 293
cells with a lacZ-containing expression plasmid (pSG5lacZ),
it was found that a NC liposome-plasmid DNA formulation
containing 12 weight % DOTAP gave the best results when
DNA concentration was ∼8 mg/mL. This translated to a
DNA-to-DOTAP ratio of 0.4 µg/nmol. It was also found that
ratios lower than this were not as efficient. Further, dioleoy-
loxydimethylammoniopropane (DODAP) was not effective as
a replacement for DOTAP.
We then determined how different methods for the prepara-
tion of a topical liposome-DNA formulation affected the
integrity of the expression plasmid DNA. Liposome-DNA
formulations were initially prepared by simple mixing followed
by sonication according to previously described methods.8
Examination of the resulting formulations by electrophoresis
in agarose gels revealed that sonication of the liposome-DNA
mixture results in physical fragmentation of the plasmid DNA
(data not shown). We then developed a preparation method
that employed sonication of the liposomes prior to addition of
the plasmid DNA. This method yielded formulations that
were more uniform in size (mean particle size ) 100 ( 20 nm
compared with a mean particle size of 500 ( 100 nm for the
unsonicated NC liposomes). Addition of plasmid DNA to the
sonicated liposomes did not reveal evidence of fragmentation
or degradation of the plasmid DNA, as determined by elec-
trophoresis of the topical formulations in agarose gels. The
particle size of the NC liposome-plasmid DNA formulation
could not be quantitatively determined; however, the mean
particle size was >2 µm.
The ability of these novel topical formulations to deliver
plasmid DNA into the hair follicles of intact hamster ear skin
was then studied with fluorescently labeled plasmid DNA and
laser scanning confocal microscopy (LCSM) to determine the
location of the plasmid DNA. Plasmid DNA was visualized
within the perifollicular regions of the skin 6 h (Figure 1,
panels A and B) after topical application of a single dose of
the NC liposomal-DNA formulation. Although some of the
plasmid DNA continued to be visualized on the skin surface
6 h after application (Figure 1, panel A), the delivery of the
labeled DNA into the hair follicles and perifollicular glands
appeared to be complete by 24 h post administration (Figure
1, panels C, D, and E). Control animals treated with an
aqueous formulation containing an equivalent dose of the
fluorescently labeled plasmid DNA failed to show evidence of
DNA beyond the superficial epidermis 24 h after topical
application (Figure 1, panel F). This result indicates that
perifollicular delivery is a physicochemical property specific
to NC liposomal formulations. Because the intensity of
ethidium bromide fluorescence is directly proportional to the
amount of double-stranded DNA present in the formulation,
these qualitative results also suggest that some of the plasmid
DNA was delivered to the region of the pilosebaceous unit in
the form of nondegraded plasmid.29
The qualitative results identified in Figure 1 were confirmed
by molecular analysis of the treated skin for the presence of
intact plasmid DNA. Whole cellular DNA was isolated from
the treated skin and subjected to Southern hybridization with
radiolabeled probes specific for the human IL-1ra cDNA.
Bands specific for pSG5IL-1ra (arrows) were observed in the
NC liposome-treated skin beginning 6 h after administration
(Figure 2). Qualitatively, the amount of pSG5IL-1ra present
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within the skin remained constant from 12 to 24 h after
treatment. From 12 to 24 h post treatment, some of the
plasmid DNA was in the form of closed circular (cc) or
linearized plasmid (linear) that was present within a broad
band of plasmid degradation products. No distinct bands
corresponding to supercoiled (sc) plasmid DNA were resolved
by these techniques. No bands were observed in the genomic
DNA obtained from animals treated with liposomes alone (C).
The results of these experiments (Figure 2) indicate that most
of the nondegraded plasmid DNA present within the skin
continued to exist in the form of closed circular or linearized
plasmid. Analysis of skin samples obtained at various times
after the topical application of a single dose showed similar
amounts of expression plasmid DNA present within the skin
from 12 to 24 h after treatment. These results indicate that
for the first 24 h post-administration, some of the plasmid
was delivered intracellularly and may have been protected
from digestion by extracellular nucleases.
We next tested the ability of the NC liposomal-plasmid
DNA formulation to mediate transfection of the perifollicular
cells proximal to the in vivo location of the delivered expres-
sion plasmid DNA. The in vivo expression of transgenic
human IL-1ra was initially detected by in situ immunohis-
tochemical staining with a monoclonal antibody specific for
the human IL-1ra protein. As shown in Figure 3, the NC
liposomal formulation also functioned as a transfecting re-
agent. Transfected human Il-1ra expressing cells, stained red,
were identified within the follicles in the proximal third of
the hair shaft (Figure 3A) and occasionally at the base of the
hair shaft (Figure 3B). Negative controls treated with aque-
ous formulations of expression plasmid DNA, or with lipo-
somes alone, failed to show evidence for IL-1ra expressing
perifollicular cells. Analysis of serial sections obtained from
multiple animals indicated that the efficiency of transfection
as measured by our immunohistochemical methods was
consistently <1% of the total perifollicular cells examined.
We then examined the kinetics of hIL-1ra expression within
treated skin over an 8 day period following a multiple-dose
(twice daily for three days), topical application protocol.
Transgenic expression of human IL-1ra in the skin of the
ventral ear was detected at its highest levels on day 1 after
application of the final topical dose. The levels of transgene
expression remained significantly above control values (p <
0.005) on days 1-5, and had returned progressively to
baseline levels by day 8 (Figure 4A). Ear cartilage and dorsal
skin were also assayed for transgenic human IL-1ra; however,
all of these values were at or below the detection limits of the
ELISA (29 pg/mL) and no significant differences were ob-
served between animals treated with NC liposomal-DNA
formulation and those treated with NC liposomes alone
(Figures 4B and 4C). It was also found that samples of ventral
ear, glands, cartilage, and dorsal skin obtained from control
animals treated with NC liposomes + pSG5lacZ plasmid DNA
exhibited transgenic human IL-1ra levels that were below the
detection limits of the assay. In addition, no transgenic
human IL-1ra was detected in the serum of the treated or
control animals (data not shown). These results suggest that
expression of transgenic protein is confined to tissues locally
targeted by the NC liposomal pSG5IL-1ra plasmid DNA
formulation, and that the diffusion of transgenic IL-1ra-
protein is largely confined to the microenvironment proximal
to the point of topical application. These results corroborate
immunohistochemical analysis of treated skin (Figure 3)
showing expression of transgenic hIL-1ra in vivo.
The dynamics of plasmid-mediated hIL-1ra expression
obtained in vivo from the NC liposome-plasmid DNA formu-
lation were then compared with those associated with a
conventional PC liposome carrier system. Although the
charged lipid-to-DNA ratios were different for the two formu-
lations, the total dose of DNA applied to the hamster ears
were identical for the two systems. Under these conditions,
it was found that the NC liposome-plasmid DNA formulation
mediated levels of transgene expression that were approxi-
mately four times higher than those obtained with the PC
liposome-plasmid DNA formulation (p < 0.001, Figure 5). Of
note is the fact that levels of human IL-1ra protein detected
in animals treated with PC liposome-plasmid DNA formula-
tions were not significantly different from the levels detected
in animals treated with PC liposomes alone (p ) 0.991) or
NC liposomes alone (p ) 0.915).
Discussion
Although the immunopathological pathways that are as-
sociated with human skin diseases are complex, interleukin-1
has been implicated as an important pathophysiological
cytokine in seborrheic eczema, psoriasis, and alopecia areata.1-5
IL-1ra protein is a well characterized competitive inhibitor
of IL-1 that is produced by several types of skin cells, including
monocytes, macrophages, fibroblasts, keratinocytes, and poly-
morphonuclear leukocytes.23,30-35 Previous studies have sug-
gested that introduction of excess IL-1ra (10-100-fold) proxi-
mal to IL-1-responsive skin cells may inhibit the patho-
physiological effects of endogenous IL-1. Preclinical and
clinical studies are being carried out to determine therapeutic
uses of recombinant IL-1ra protein for the treatment of a wide
variety of human diseases, including those with a primary
manifestation in skin.36
Transfection of the IL-1ra transgene directly into cells at
the site of disease activity promises to be a much more
effective method for delivery of IL-1ra protein than the
repeated application of purified recombinant protein. If the
efficiency of skin cell transfection could be improved, the
ability to deliver the gene vector via topical application would
be advantageous in terms of both feasibility and total costs.
The successful development of topical gene therapy represents
a two-step drug delivery process; the first step involves the
delivery of biologically functional (nondegraded) nucleic acids
Figure 1sHistologic localization of plasmid DNA in hamster skin following single-dose topical application of nonionic-cationic (NC) liposomes containing pSG5IL-1ra
DNA or aqueous pSG5IL-1ra DNA. At 6 h following application, labeled plasmid was observed along the epidermal surface as well as within the follicles (Panels A and
B, 40X). At 24 h following application, the plasmid was present within multiple follicles (Panels C, 40X; D, 10X; and E, 40X). At 24 h following application of aqueous
control solution, no evidence of plasmid was found within the follicles or elsewhere in the skin (Panel F, 40X). Auricular cartilage separating ventral and dorsal skin
surfaces appears as a longitudinal band across Panels B−F.
Figure 2sHybridization analysis of total cellular DNA obtained from skin treated
with a single dose of NC liposomes with or without pSG5IL-1ra DNA. Key:
(numbers above lanes) hours post treatment; (C) control animals; (sc) supercoiled
(cc) closed circular.
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to anatomical regions proximal to skin cells, and the second
step involves delivery of nucleic acids across the cell mem-
brane of these cells. Together, these processes effect trans-
fection of these cells in vivo and result in observable biological
responses. This study was designed to test the hypothesis
that novel NC liposome-plasmid DNA formulations could be
developed that would enhance delivery of expression plasmid
DNA to perifollicular cells and mediate transfection in vivo.
Because focal overexpression of transgenic IL-1ra in areas of
skin affected with these diseases might be of therapeutic
value, we chose to examine the IL-1ra cDNA as a functional
transgene.
In this report, we present data showing that hybrid non-
ionic/cationic liposomes combined with an eukaryotic expres-
sion plasmid encoding the cDNA for human IL-1ra can
mediate overexpression of the IL-1ra protein after topical
application to the hamster ear in vivo. To test the first phase
of the drug delivery process, we performed an in vivo targeting
experiment. It is clear from the results of this experiment
(Figure 1) that the novel NC liposomal-plasmid DNA formu-
lations are able to deliver plasmid DNA into the proximal
third of the hair shaft within the follicles and the sebaceous
glands present within these follicles. This delivery process
was temporally progressive over a period of ∼1 day and
suggests that it is neither energy dependent nor kinetically
saturable. These results are consistent with our previous
studies with NC liposomes for the delivery of recombinant
proteins into skin and support the hypothesis that the ability
of the NC liposomes to deliver plasmid DNA into the follicles
is an inherent physicochemical property of the liposomes
themselves.
The ability of the NC liposomes to also facilitate transfection
in vivo is supported by the results of the molecular (Figure 2)
and immunohistochemical (Figure 3) analyses of treated skin.
Because the treated skin was stripped of hair and washed
prior to these analyses, we believe it is unlikely that a
significant amount of the DNA identified by Southern analysis
represents plasmid bound to follicular proteins. Although
retention of plasmid DNA in an extracellular compartment
cannot be excluded on the basis of this experiment, we believe
Figure 4sExpression of human IL-1ra in various strata of the hamster ear following
topical in vivo application of nonionic/cationic (NC) liposomes with and without
plasmid DNA. Assays were performed in triplicate and results are expressed as
picograms of IL-1ra/cm2 of treated skin surface area. Data points represent means
± standard error (n ) 4). Levels of human IL-1ra recovered from NC liposome
+ DNA-treated animals were significantly above levels of IL-1ra present in controls
treated with NC liposomes alone on days 1−5 (p < 0.005) and had returned to
baseline levels by day 8. No significant differences between NC liposome + DNA-
treated and NC liposome-treated controls were identified in any other skin strata
analyzed: Panel A ) ventral skin; Panel B ) auricular cartilage; and Panel C )
dorsal skin.
Figure 5sExpression of transgenic human IL-1ra in the ventral ear of the hamster
following topical in vivo application of nonionic/cationic (NC) and phospholipid/
cationic (PC) liposome formulations with and without pSG5IL-1ra plasmid DNA.
Assays were performed in triplicate and the results are expressed as picograms
of IL-1ra/cm2 of treated skin surface area. Ears treated with the NC liposomes +
DNA and NC liposomes alone resulted in expression of 165.5 ± 15.6 and 31.4
± 24.0 pg/cm2 of human IL-1ra, respectively. Ears treated with PC liposomes +
DNA resulted in 40.8 ± 8.1 pg/cm2 of human IL-1ra. The mean levels of human
IL-1ra obtained with PC liposomes alone were below the limits of detection of the
ELISA (<29 pg/cm2). Controls treated with DNA alone expressed a mean of 32.5
± 11.0 pg/cm2 of human IL-1ra. Vertical bars indicate mean values ± standard
error obtained from multiple animals (n ) 6).
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that the results indicate that an appreciable amount of the
expression plasmid DNA is delivered intracellularly. Intra-
cellular expression of transgenic protein by perifollicular
fibroblasts in vivo was identified by a monoclonal antibody
specific for the human IL-1ra protein.
The dynamics of hIL-1ra expression in vivo were deter-
mined by a multidose topical application protocol (Figure 4).
Levels of hIL-1ra transgene expression achieved within the
ventral skin were significant and statistically equivalent at
1, 3, and 5 days post treatment. This result suggests that it
may be possible to achieve a steady-state level of transgene
expression in vivo with a daily application schedule. Twice
or thrice daily application schedules are a well-established
standard for the use of topical formulations that contain
conventional pharmaceutical drugs.
In summary, we believe that our results confirm the ability
of hybrid NC liposomes to facilitate the delivery of plasmid
DNA to skin cells beyond the superficial epidermis and
mediate transient transfection of these cells in vivo. Our
results are qualitatively and quantitatively different (Figure
5) from previous data suggesting that determinations of the
utility of conventional cationic liposome-mediated topical gene
therapy based on observations with a marker transgene8,9 may
be limited. Importantly, the dynamics and kinetics of regional
transgenic soluble protein expression were quantitatively
determined for a biologically active and potentially therapeutic
immunomodulatory transgene, human IL-1ra. Alternative
explanations for the observed levels of immunoreactive IL-
1ra present within the NC liposome-plasma DNA-treated
skin were explored and excluded. Further refinement of NC
liposome formulations combined with improved expression
plasmids and extensive in vivo studies promises to allow the
development of topical gene therapy systems that may be
appropriate for the initiation of human clinical trials.
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